Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.285
-0.530-5.40%
Volume:92.21M
Turnover:878.44M
Market Cap:106.98B
PE:23.34
High:10.040
Open:9.880
Low:9.235
Close:9.815
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.56
T/O Rate:0.80%
Dividend:0.34
Dividend Rate:3.64%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.43
PE(LYR):23.34
PS:2.92

Loading ...

CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials

MT Newswires Live
·
Sep 08

CSPC Wins China Clinical Trial Approval for Syh2083 Dry Eye Drops

Reuters
·
Sep 08

CSPC Pharmaceutical - Syh2083 Eye Drops Obtain Clinical Trial Approval in China

THOMSON REUTERS
·
Sep 08

CSPC Pharmaceutical Group Stock Falls 2.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 08

Market Bets on BOJ Rate Hike While CICC's Merger Wins Regulatory Approval

Stock News
·
Sep 08

CSPC Pharma Begins Phase II Study of Influenza Drug in China

MT Newswires Live
·
Sep 07

Fourth Breakthrough Therapy Designation Granted to EGFR-Targeted ADC Developed by CSPC

Deep News
·
Sep 07

CSPC Pharma Initiates Phase II Trial of SYH2085 Tablet for Uncomplicated Influenza in Chinese Adults

Stock News
·
Sep 07

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Dow Jones
·
Sep 03

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Deep News
·
Sep 03

Movement Alert|CSPC PHARMA Rises 3.11% in Regular Trading, Multiple Pipeline Milestones Drive Momentum

Market Focus
·
Sep 03

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Reuters
·
Sep 01

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live
·
Sep 01

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live
·
Sep 01

CSPC Pharma Launches Phase I Trial of Novel 5-HT2A Partial Agonist SYH2056 for Depression in China

Bulletin Express
·
Sep 01

CSPC Pharma Secures Third NMPA Breakthrough Therapy Designation for EGFR-Targeting ADC SYS6010 in Recurrent/Metastatic Head-and-Neck Cancer

Bulletin Express
·
Sep 01

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc

THOMSON REUTERS
·
Sep 01

CSPC Pharma Begins Trial for Weight Management Drug in China

MT Newswires Live
·
Aug 31

CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management

Bulletin Express
·
Aug 31

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

Stock News
·
Aug 31